Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice
NYL Pang, ASR Pang, VT Chow, DY Wang - Military Medical Research, 2021 - Springer
SARS-CoV-2 is a newly identified member of the coronavirus family that has caused the
Coronavirus disease 2019 (COVID-19) pandemic. This rapidly evolving and unrelenting …
Coronavirus disease 2019 (COVID-19) pandemic. This rapidly evolving and unrelenting …
Broadly-neutralizing antibodies against emerging SARS-CoV-2 variants
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
have become a major concern in the containment of current pandemic. The variants …
have become a major concern in the containment of current pandemic. The variants …
Molecular insights into receptor binding energetics and neutralization of SARS-CoV-2 variants
Despite an unprecedented global gain in knowledge since the emergence of SARS-CoV-2,
almost all mechanistic knowledge related to the molecular and cellular details of viral …
almost all mechanistic knowledge related to the molecular and cellular details of viral …
Passive immunotherapy against SARS-CoV-2: from plasma-based therapy to single potent antibodies in the race to stay ahead of the variants
The COVID-19 pandemic is now approaching 2 years old, with more than 440 million people
infected and nearly six million dead worldwide, making it the most significant pandemic …
infected and nearly six million dead worldwide, making it the most significant pandemic …
Monoclonal antibody therapies in the management of SARS-CoV-2 infection
E Miguez-Rey, D Choi, S Kim, S Yoon… - Expert Opinion on …, 2022 - Taylor & Francis
ABSTRACT Introduction Neutralizing antibodies (NAbs) that target key domains of the spike
protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may have …
protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may have …
Monoclonal antibodies against SARS-CoV-2: current scenario and future perspectives
E Quiros-Roldan, S Amadasi, I Zanella, M Degli Antoni… - Pharmaceuticals, 2021 - mdpi.com
Monoclonal antibodies (mAbs) have been known since the 1970s. However, their
therapeutic potential in the medical field has recently emerged, with the advancement of …
therapeutic potential in the medical field has recently emerged, with the advancement of …
[HTML][HTML] Current treatment strategies for COVID‑19
F Han, Y Liu, M Mo, J Chen… - Molecular …, 2021 - spandidos-publications.com
The spread of the novel severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2)
emerged suddenly at the end of 2019 and the disease came to be known as coronavirus …
emerged suddenly at the end of 2019 and the disease came to be known as coronavirus …
Mathematical modeling and analysis of the dynamics of RNA viruses in presence of immunity and treatment: A case study of SARS-CoV-2
The emergence of novel RNA viruses like SARS-CoV-2 poses a greater threat to human
health. Thus, the main objective of this article is to develop a new mathematical model with a …
health. Thus, the main objective of this article is to develop a new mathematical model with a …
Anti-SARS-CoV-2 immunoglobulin isotypes, and neutralization activity against viral variants, according to BNT162b2-vaccination and infection history
M Tarkowski, W de Jager, M Schiuma… - Frontiers in …, 2021 - frontiersin.org
Purpose To compare SARS-CoV-2 antigen-specific antibody production and plasma
neutralizing capacity against B. 1 wild-type-like strain, and Gamma/P. 1 and Delta/B. 1.617 …
neutralizing capacity against B. 1 wild-type-like strain, and Gamma/P. 1 and Delta/B. 1.617 …
The emergence of SARS-CoV-2 variants threatens to decrease the efficacy of neutralizing antibodies and vaccines
The novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is
the cause of the coronavirus disease (COVID-19) pandemic. As of August 2021, more than …
the cause of the coronavirus disease (COVID-19) pandemic. As of August 2021, more than …